International Journal of Gynecology & Obstetrics
Volume 104, Issue 3 , Pages 189-193, March 2009

Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India

  • Tori Sutherland

      Affiliations

    • Department of Obstetrics and Gynecology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA
    • Corresponding Author InformationCorresponding author. Academic and Administrative Office, Department of Obstetrics and Gynecology, 4940 Eastern Avenue, Baltimore, MD 21224-2780, USA. Tel.: +1 443 849 8053; fax: +1 410 550 0245.
  • ,
  • David M. Bishai

      Affiliations

    • Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Received 23 July 2008; received in revised form 29 September 2008; accepted 14 October 2008. published online 12 December 2008.

Abstract 

Objective

To determine the cost-effectiveness of prenatal iron supplementation and misoprostol use as interventions to prevent maternal mortality in home births in rural India.

Methods

A cost-effectiveness analysis depicted three hypothetical cohorts of 10000 pregnant women delivering at home in rural India: one with no intervention, one receiving standard prenatal iron supplements, and 1 receiving 600 µg of misoprostol in the third stage of labor.

Results

Misoprostol used to prevent postpartum hemorrhage resulted in a 38% (95% CI, 5%–73%) decrease in maternal deaths, while prenatal iron supplementation resulted in a 5% (95% CI, 0%–47%) decrease. Misoprostol cost a median US $1401 (IQR US $1008–$1848) prenatal iron supplementation cost a median US $2241 (IQR No Lives Saved–$3882) per life saved compared with the standard care outcome.

Conclusion

Misoprostol is a cost-effective maternal mortality intervention for home births. Iron supplementation may be worthwhile to improve women's health, but it is uncertain whether it can prevent mortality after hemorrhage.

Keywords: Cost-effectiveness, Home birth, Iron supplementation, Maternal mortality, Misoprostol

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0020-7292(08)00459-1

doi:10.1016/j.ijgo.2008.10.011

International Journal of Gynecology & Obstetrics
Volume 104, Issue 3 , Pages 189-193, March 2009